205 related articles for article (PubMed ID: 26402634)
1. Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study.
Burnham SC; Raghavan N; Wilson W; Baker D; Ropacki MT; Novak G; Ames D; Ellis K; Martins RN; Maruff P; Masters CL; Romano G; Rowe CC; Savage G; Macaulay SL; Narayan VA; ;
J Alzheimers Dis; 2015; 46(4):1079-89. PubMed ID: 26402634
[TBL] [Abstract][Full Text] [Related]
2. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
Rembach A; Watt AD; Wilson WJ; Villemagne VL; Burnham SC; Ellis KA; Maruff P; Ames D; Rowe CC; Macaulay SL; Bush AI; Martins RN; Masters CL; Doecke JD;
J Alzheimers Dis; 2014; 40(1):95-104. PubMed ID: 24334723
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
[No Abstract] [Full Text] [Related]
4. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease.
Ellis KA; Bush AI; Darby D; De Fazio D; Foster J; Hudson P; Lautenschlager NT; Lenzo N; Martins RN; Maruff P; Masters C; Milner A; Pike K; Rowe C; Savage G; Szoeke C; Taddei K; Villemagne V; Woodward M; Ames D;
Int Psychogeriatr; 2009 Aug; 21(4):672-87. PubMed ID: 19470201
[TBL] [Abstract][Full Text] [Related]
5. Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative.
Ellis KA; Rowe CC; Villemagne VL; Martins RN; Masters CL; Salvado O; Szoeke C; Ames D;
Alzheimers Dement; 2010 May; 6(3):291-6. PubMed ID: 20451879
[TBL] [Abstract][Full Text] [Related]
6. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
[TBL] [Abstract][Full Text] [Related]
7. Minimizing the Sample Sizes of Clinical Trials on Preclinical and Early Symptomatic Stage of Alzheimer Disease.
Luo J; Weng H; Morris JC; Xiong C
J Prev Alzheimers Dis; 2018; 5(2):110-119. PubMed ID: 29616704
[TBL] [Abstract][Full Text] [Related]
8. Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS).
Lim YY; Jaeger J; Harrington K; Ashwood T; Ellis KA; Stöffler A; Szoeke C; Lachovitzki R; Martins RN; Villemagne VL; Bush A; Masters CL; Rowe CC; Ames D; Darby D; Maruff P
Arch Clin Neuropsychol; 2013 Jun; 28(4):320-30. PubMed ID: 23552802
[TBL] [Abstract][Full Text] [Related]
9. Sex-specific composite scales for longitudinal studies of incipient Alzheimer's disease.
Banks SJ; Shifflett B; Berg JL; Sundermann E; Peavy G; Bondi MW; Edland SD
Alzheimers Dement (N Y); 2019; 5():508-514. PubMed ID: 31650007
[TBL] [Abstract][Full Text] [Related]
10. Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing.
Sona A; Zhang P; Ames D; Bush AI; Lautenschlager NT; Martins RN; Masters CL; Rowe CC; Szoeke C; Taddei K; Ellis KA;
Int Psychogeriatr; 2012 Feb; 24(2):197-204. PubMed ID: 21749739
[TBL] [Abstract][Full Text] [Related]
11. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.
Langbaum JB; Hendrix SB; Ayutyanont N; Chen K; Fleisher AS; Shah RC; Barnes LL; Bennett DA; Tariot PN; Reiman EM
Alzheimers Dement; 2014 Nov; 10(6):666-74. PubMed ID: 24751827
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C
Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282
[TBL] [Abstract][Full Text] [Related]
13. Profiles of Cognitive Change in Preclinical and Prodromal Alzheimer's Disease Using Change-Point Analysis.
Williams OA; An Y; Armstrong NM; Kitner-Triolo M; Ferrucci L; Resnick SM
J Alzheimers Dis; 2020; 75(4):1169-1180. PubMed ID: 32390623
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.
Pietrzak RH; Lim YY; Neumeister A; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Restrepo C; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P;
JAMA Psychiatry; 2015 Mar; 72(3):284-91. PubMed ID: 25629787
[TBL] [Abstract][Full Text] [Related]
15. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials.
Wang J; Logovinsky V; Hendrix SB; Stanworth SH; Perdomo C; Xu L; Dhadda S; Do I; Rabe M; Luthman J; Cummings J; Satlin A
J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):993-9. PubMed ID: 27010616
[TBL] [Abstract][Full Text] [Related]
16. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis.
Parnetti L; Chipi E; Salvadori N; D'Andrea K; Eusebi P
Alzheimers Res Ther; 2019 Jan; 11(1):7. PubMed ID: 30646955
[TBL] [Abstract][Full Text] [Related]
18. Epileptic Prodromal Alzheimer's Disease, a Retrospective Study of 13 New Cases: Expanding the Spectrum of Alzheimer's Disease to an Epileptic Variant?
Cretin B; Sellal F; Philippi N; Bousiges O; Di Bitonto L; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016 Apr; 52(3):1125-33. PubMed ID: 27104892
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial.
Di Stefano F; Epelbaum S; Coley N; Cantet C; Ousset PJ; Hampel H; Bakardjian H; Lista S; Vellas B; Dubois B; Andrieu S;
J Alzheimers Dis; 2015; 48(3):793-804. PubMed ID: 26402073
[TBL] [Abstract][Full Text] [Related]
20. Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.
Borland E; Edgar C; Stomrud E; Cullen N; Hansson O; Palmqvist S
Neurology; 2022 Sep; 99(11):e1142-e1153. PubMed ID: 35835560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
